ArticleFrontiers in pharmacology2025
A high-efficiency automatic pressure-relief drug transfer device for anticancer medications with superior closed performance.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Preventing exposure to hazardous drugs is crucial for healthcare workers to avoid health risks. To mitigate healthcare workers' risks when handling hazardous drugs, we developed a novel closed-system drug-transfer device (CSTD) called CSTD(JLY). This CSTD has an automatic pressure-relief structure. Hence, it can significantly decrease the resistance in the push/pull of a piston rod if an operator transfers drugs, thereby reducing the burden on the hands of the operator during drug transfer. Methods: We investigated the closed performance of the novel CSTD (JLY) by comparing it with the performance of a syringe. We selected a simulation drug (fluorescein sodium), commonly used drugs (lansoprazole, nimodipine, and tropisetron), and a commonly used anti-cancer agent (cyclophosphamide) to conduct exposure evaluation. Results: Compared with a syringe, CSTD(JLY) could reduce drug leakage significantly. Our novel CSTD with an automatic pressure-relief structure had superior closed performance. CSTD(JLY) could solve the problem of liquid-drug leakage during drug transfer. Conclusion: This feature could reduce the exposure risk healthcare workers and patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.